Galera Therapeutics Inc
OTC:GRTX
Galera Therapeutics Inc
Common Shares Outstanding
Galera Therapeutics Inc
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Galera Therapeutics Inc
OTC:GRTX
|
Common Shares Outstanding
$75.5m
|
CAGR 3-Years
42%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Common Shares Outstanding
$1.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
1%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Common Shares Outstanding
$1.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Common Shares Outstanding
$537.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Common Shares Outstanding
$257m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Common Shares Outstanding
$108.2m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
Galera Therapeutics Inc
Glance View
Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Malvern, Pennsylvania and currently employs 30 full-time employees. The company went IPO on 2019-11-07. The firm is focused on developing and commercializing a pipeline of therapeutics to transform radiotherapy in cancer. The firm's lead product candidate, avasopasem manganese (GC4419), is a potent and selective small molecule dismutase mimetic, which is developed for the reduction of severe oral mucositis (SOM). The company is also developing a second dismutase mimetic product candidate, GC4711, to increase the anti-cancer efficacy of stereotactic body radiation therapy (SBRT). The company is evaluating GC4419 in a Phase III registrational trial (ROMAN trial) to reduce the incidence and severity of SOM induced by radiotherapy in patients with head and neck cancer (HNC), its lead indication. The firm is also evaluating GC4711 in combination with SBRT in a Phase I/II safety and anti-cancer efficacy trial in non-small cell lung cancer and a Phase IIb trial of GC4711 in combination with SBRT in patients with pancreatic cancer.
See Also
What is Galera Therapeutics Inc's Common Shares Outstanding?
Common Shares Outstanding
75.5m
USD
Based on the financial report for Dec 31, 2024, Galera Therapeutics Inc's Common Shares Outstanding amounts to 75.5m USD.
What is Galera Therapeutics Inc's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 5Y
25%
Over the last year, the Common Shares Outstanding growth was 39%. The average annual Common Shares Outstanding growth rates for Galera Therapeutics Inc have been 42% over the past three years , 25% over the past five years .
You don't have any saved screeners yet